rhs1

Anti-Retroviral Drugs

Hetero has been committed towards HIV/AIDS treatment since 1997 and today it is recognized as one of the global leaders for producing and supplying affordable ARV APIs and Formulations. With our 30+ ARV combinations catering to about 40% of identified HIV/AIDS patients’ treatment*’, we are a source of hope for millions worldwide.

Buoyed by a dedicated R & D and expansive manufacturing facilities, we are able to consistently expand our capabilities to meet the growing demand for ARV medicines. Our commitment to the cause has seen us emerge as a partner of choice for renowned global procurement agencies.

*One in every three HIV/AIDS patients in the world trusts Hetero’s ARV medicines.

*Ref: 1. UNAIDS Data 2017. 2. Global AIDS Update 2017. 3. UNAIDS.org. 4. Either API or FDF, Data on file
arv2